Loading...

Home
ETF
CELUW

CELUW

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CELUW News

Celularity Announces Chief Financial Officer Transition

Jun 10 2025Newsfilter

Celularity Announces Full Year 2024 Operating and Financial Results

May 09 2025Newsfilter

MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs

Jan 27 2025Newsfilter

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 10 2024Newsfilter

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 06 2024Newsfilter

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 27 2024Newsfilter

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 20 2024Newsfilter

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Nov 18 2024Newsfilter

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Nov 07 2024Newsfilter

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 23 2024Newsfilter

Celularity Provides Corporate Update

Oct 22 2024Newsfilter

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16 2024Newsfilter

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 28 2024Newsfilter

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 03 2024newsfilter

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 20 2024newsfilter

Celularity Announces 1-for-10 Reverse Stock Split

Feb 23 2024businesswire